Skip Navigation LinksHome > July 2013 - Volume 32 - Issue 7 > Topical Ranibizumab as a Treatment of Corneal Neovasculariza...
doi: 10.1097/ICO.0b013e3182775f8d
Clinical Science

Topical Ranibizumab as a Treatment of Corneal Neovascularization

Ferrari, Giulio MD*; Dastjerdi, Mohammad H. MD; Okanobo, Andre MD; Cheng, Sheng-Fu MD; Amparo, Francisco MD; Nallasamy, Nambi; Dana, Reza MD, MSc, MPH

Supplemental Author Material
Collapse Box


Purpose: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV).

Methods: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA.

Results: Statistically significant decreases in neovascular area (55.3%, P < 0.001), which lasted through 16 weeks, and VC (59%, P < 0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted.

Conclusions: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.

© 2013 by Lippincott Williams & Wilkins.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.